IRCSS San Martino Ist
Prof. Antonio Uccelli
The San Martino Hospital has always been a health reference point. It is an institution with five centuries of history and represents the primary health ‘hub’ in Liguria, attracting patients from the metropolitan area, from the inside of Liguria and outside the region.
After the University Hospital San Martino and the scientific Tumor Institute merged, both in the same city, on 1 September 2021, the University Hospital IRCCS San Martino IST National Institute for the Cancer Research was established, specializing in haemato-oncology.
With Regional Law no. 29 of 28/12/2017, the Institute took the name “IRCCS Polyclinic Hospital San Martino.” On 5 March 2018, the Institute also obtained recognition for a second discipline, “Neuroscience.”
The Institute houses the didactic centre of the Medical and Pharmaceutical Sciences School, which includes the Degree Course in Medicine and Surgery, Postgraduate Diplomas, Research Doctorates, Level I and II Masters and Degree Courses in the health professions.
The hospital is a city within a city, with around five thousand employees and 35 hectares of land on which the complex extends, crossed by 12 km of avenues. The hospital is easily reachable from the thoroughfare and railways and is even served by urban and suburban public transport.
The Institute provides diagnosis and treatment of illnesses on an inpatient basis according to macro-activities: hospitalization, day hospital, day surgery, operating blocks, outpatient and surgical clinics, diagnostic services, support services, complex outpatient services, outpatient day services.
In addition to offering all principal specialistic medical and surgical services, Polyclinic San Martino retains medical features that place it at the forefront in the diagnosis and treatment of major haemato-oncological diseases, with a range of activities from acute leukemia to bone marrow transplants and solid tumours classified as “big-killers.” A large number of cases gives the resources to clinical studies on chemotherapeutic drugs and also on new molecularly targeted drugs. In addition, the large number of cases enables translational studies to be carried out on the ‘mechanisms of oncological disease’ on material from patients investigated in vitro in the laboratory using the latest technology.
Consult the individual files of our Members